# Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma

> **NCT05143112** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen University General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma,B Cell

## Interventions

- **BIOLOGICAL:** Allogeneic CD19 CR-T cell

## Key facts

- **NCT ID:** NCT05143112
- **Lead sponsor:** Shenzhen University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-05
- **Primary completion:** 2024-02
- **Final completion:** 2024-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143112, "Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05143112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*